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64 Poster Session-Iupregulation of CDKN2A and XAF1 expressions correlate with
downregulation of their downstream target proteins including phos-
phorylated Rb and XIAP, respectively. Based on the present data and
our previously published results, the synergistic effects of DAC and
Bu involve cell cycle arrest and apoptosis induction. Our results sug-
gest that DNA methylation status may be used to identify leukemia
patients who could benefit from Bu-DAC combinations to achieve
improved leukemic cytoreduction with the conditioning program
prior to stem cell transplantation.171
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) AFTER FIRST RE-
LAPSE IN ADULT PATIENTS WITH ACUTE LYMPHOCYTIC LEUKEMIA
(ALL)
Arnold, R.1, Terwey, T.1, Hemmati, P.1, le Coutre, P.1, Neuburger, S.1,
Dorken, B.1, Massenkeil, G.2, Gokbuget, N.3 1 Charite University Medi-
cine, Berlin, Germany; 2 Klinikum Gu¨tersloh, Guetersloh, NRW,
Germany; 3 Frankfurt University, Frankfurt, Hessen, Germany
70 adult ALL patients (pts) were transplanted after 1. relapse
(leukemic blasts .5% in bone marrow or central nervous system
involvement) in a single center between 1995 and 2007. 2 pts
were excluded from the analysis because diagnosis of ALL was
made in childhood and they were transplanted in adult age. Median
age of the analyzed 68 pts was 28 years (16–54). 43 pts were male,
25 female. 32 pts were transplanted in 1. relapse, 24 pts in CR2 and
12 pts beyond CR2 (.CR2). Stem cell donors were HLA identical
sibling (n 5 24), identical twin (n 5 1), HLA identical child (n 5 1)
and unrelated donors (n 5 42). Standard conditioning was
12GyTBI and cyclophosphamide (CY) or VP16 (myeloablative
conditioning 5 MAC). Pts with comorbidities and contraindica-
tions against MAC received a dose reduced regimen (RIC) with
FLUD, BU and ATG (n 5 3). 18/68 pts (26%) are alive in
CCR, 50/68 pts (74%) are dead. Causes of death were leukemia
in 30/50 and transplant related morbidity, TRM in 20/50 pts
(GvHD and/or infection). For the whole patient group, probability
of survival (prob OS) at 7 years is 0.21 as is disease free survival.
Prob TRM is 0.43. Prob OS regarding stage of disease at SCT
was 0.26 for pts transplanted in 1. relapse, 0.23 for pts transplanted
in CR2 and 0.08 for pts transplanted beyond CR2. Prob OS after
unrelated donor or family donor transplantation was not different
(0.20 vs 0.22). Influence of leukemic risk factors on the prob OS
was analyzed. Risk group at diagnosis and during chemotherapy
(standard vs high risk group, criteria according to the GMALL
Studies) had no significant influence on the prob OS: 0.18 vs
0.25. Pts with B-lineage ALL had a prob OS of 0.25 vs 0.08 in
pts with T-lineage (n. s.). The median duration of 1. remission
for all pts was 9 months (1–72). Prob OS for pts with a remission
duration #9 months or .9 months was 0.24 and 0.17, resp. In con-
clusion, allogeneic SCT can cure ALL pts after 1. clinical relapse.
Our data show a high relapse rate even after standard conditioning
with 12GyTBI. Since conditioning can not be intensified further
because of high TRM, another transplant strategy should be dis-
cussed. Analysis of minimal residual disease (MRD) should be
done regularly during therapy and follow up of ALL pts. If molec-
ular relapse is detected, allogeneic SCT should be performed im-
mediately to avoid therapy refractory clinical relapse. In this
setting 5 pts with MRD positivity were transplanted in CR1 and
4/5 pts are alive in CCR.172
SAFETY AND EFFICACY OF FLUDARABINE AND PK-TARGETED INTRAVE-
NOUS BUSULFAN BEFORE ALLOGRAFTING FOR ADULT ALL
Anasetti, C., Santarone, S., Alsina, M., Ayala, E., Field, T., Kharfan-
Dabaja, M., Ochoa, L., Perez, L., Perkins, J., Raychaudhuri, J.,
Sullivan, D., Fernandez, H. Moffitt Cancer Center, Tampa, FL
Remission consolidation with allogeneic blood or marrow trans-
plantation improves survival of young patients with acute lymphoid
leukemia (ALL), but the potential benefit of transplantation in older
patients is offset by regimen toxicity and non-relapse mortality. Bu-
sulfan is not thought to be an effective drug for ALL, presumably be-
cause of intrinsic resistance of ALL to alkylating agents, or perhapsbecause of the large variability in busulfan pharmacokinetics and er-
ratic drug exposure. Here we report results of treatment with a PK-
targeted intravenous busulfan regimen in 25 adults with ALL. Pa-
tient age was 23–55 (median 40) years, 13 were treated in first com-
plete remission, 10 in second remission, and 2 with resistant disease.
Treatment was with 4 consecutive daily doses of fludarabine 40 mg/
m2, followed by intravenous busulfan, administered on days 1 and 2
at 130–145 mg/m2 daily over 4 hours with PK-sampling and mass
spectrometry assay. On days 3 and 4 busulfan dose was adjusted to
target an average area under the concentration curve of 5300 6
530 mMol*min/L for each of the four days. Donors were siblings
(14), or unrelated (11). Grafts were T-replete, filgrastim-mobilized
hematopoietic blood cells. GVHD prophylaxis was tacrolimus plus
methotrexate or mycophenolate mofetil. Mortality from all non-
relapse causes was 4% at 100 days, and 8% at one year. The one-
year overall survival (OS) was 66%, and relapse-free survival (RFS)
was 62%, with a median follow-up of 1.3 years for live patients.
For patients transplanted in CR1, one-year OS was 77% and RFS
70%; in CR2, OS and RFS were 58%; and with resistant disease,
OS and RFS were 0%. OS was 56% in patients up to 40 years, and
67% in patients 41–55 years old, with disease status and stage simi-
larly distributed in younger and older cohorts. With this treatment
protocol, the one-year non-relapse mortality is identical to what is
observed with non-transplant therapies. When compared to irradia-
tion-containing regimens, fludarabine and PK-targeted busulfan ap-
pear much safer and similarly effective in controlling ALL, providing
a treatment option for all adult patients with ALL. A multicenter
study comparing this transplant protocol against post-remission che-
motherapy for adult ALL is warranted.173
CLOFARABINE-INDUCED REMISSION IN RELAPSED PEDIATRIC ACUTE
MYELOGENOUS LEUKEMIA
Gordon, C., Megason, G., Ledbetter, A. University of Mississippi Medical
Center, Jackson, AZ
Despite improvements, the prognosis for children with recurrent
or progressive acute myeloid leukemia (AML) remains poor; the 5-
year relative survival rate for children under age 15 yrs is 54% (Jemal,
et al.,Ca Cancer J Clin 2008). Early relapse, defined as relapse within
18 months or less from time of initial diagnosis, is associated with
a second CR rate of about 50% and an overall survival of\10%
(Stahnke, K. et al. Leuk 1998). The second generation purine nucle-
oside analog clofarabine was designed to improve on the efficacy and
safety of cladribine and fludarabine. Interest in the utility of clofara-
bine in the treatment of pediatric patients with AML was stimulated
by its Food and Drug Administration approval for the treatment of
pediatric patients with relapsed ALL previously treated with at least
2 regimens. We report on our experience using clofarabine in 6 pe-
diatric patients with relapsed AML, 4 of whom achieved complete re-
mission (CR) with this single agent. All patients received clofarabine
IV at the recommended dose of 52 mg/m2/day for 5 days, with cycles
every 2 to 6 wks depending on count recovery. Patient 1, who never
achieved CR with prior therapies, received clofarabine after she re-
lapsed 6 mos.following a bone marrow transplant (BMT); she
achievedCR after 2 treatment cycles. Despite CR, this severely ill pa-
tient ultimately died with multiple organ failure, pneumonia, and
sepsis. Patient 2 obtained a CR after one cycle of clofarabine and
CR continues after 7 cycles. However, the original plan to maintain
this patient on clofarabine for 1 yr. was not achieved because of
chronic transfusion dependent thrombocytopenia. Patient 3 achieved
a CR after one cycle of clofarabine and received an additional cycle as
maintenance while awaiting BMT. Patient 4 had a CR with one cycle
of clofarabine following a relapse after a first BMT. The patient re-
ceived 2 additional cycles as maintenance before proceeding to a 2nd
BMT. This patient relapsed after the second BMT and is currently
receiving induction with clofarabine. Patients 5 & 6 had not re-
sponded well to previous treatments and failed to respond to a single
cycle of clofarabine. Patient 5 never achieved CR despite gemtuzu-
mab and BMT. Patient 6 had an unsustained CR2 with gemtuzumab
and failed subsequent therapies. Our experience indicates that sin-
gle-agent clofarabine as induction therapy can provide durable
CRs in pediatric patients with relapsed AML and provide a bridge
to subsequent BMT.
